

ABSTRACT OF THE DISCLOSURE

The invention relates to non-slow-binding thrombin inhibitors of the formula: A-B-C-Lys-D- wherein A is H, 2-hydroxy-3-cyclohexyl-proprionyl-, R₁, R₁-O-CO-, R₁-SO₂-, -(CHR₂)_nCOOR₃, or an N-protecting group, wherein R₁ is selected from -(1-6C)alkylene-COOH, (1-12C)alkyl, (2-12C)alkenyl, (6-14C)aryl, (7-15C)aralkyl and (8-16C)aralkenyl, the aryl group of which may be substituted with (1-6C)alkyl, (2-12C)alkoxy, hydroxy, or halogen; R₂ is H or has the same meaning as R₁, R₃ is selected from H, (1-12C)alkyl, (2-12C)alkenyl, (6-14C)aryl, (7-15C)aralkyl and (8-16C)aralkenyl, the aryl group of which may be substituted with (1-6C)alkyl, (2-12C)alkoxy, hydroxy or halogen; n is an integer of 1 to 3; B is a bond, L-asp or an ester derivative thereof, Leu, norLeu, -N(benzyl)-CH₂-CO-, -N(2-indane)-CH₂-CO-, D-1 Piq, D-3 Piq, D-Tiq, Atc or a D-amino acid having a hydrophobic aromatic side chain; C is Azt, Pro, Pec, norLeu(cyclo)Gly, an amino acid of one of the formulae -N[(3-8C)cycloalkyl]-CH₂-CO- or -N(benzyl)-CH₂-CO-, D is selected from COOH, tetrazole, oxazole, thiazole and benzothiazole; or a prodrug thereof; or a pharmaceutically acceptable salt thereof, with the exception of the compound Me-D-Phe-Pro-Lys-COOH. The compounds can be used as antithrombotic agents